Presumed ocular histoplasmosis syndrome
Presumed Ocular Histoplasmosis Syndrome (POHS) is a rare eye disease that is believed to be caused by the Histoplasma capsulatum fungus. This condition is characterized by the presence of chorioretinal scars, peripapillary atrophy, and choroidal neovascularization in the absence of systemic histoplasmosis or evidence of other causes of similar ocular findings.
Etiology
The exact cause of POHS is not well understood. It is presumed to be caused by the Histoplasma capsulatum fungus, which is endemic in certain parts of the United States, particularly the Ohio River Valley and the Mississippi River Valley. However, not all individuals exposed to the fungus develop POHS, suggesting that other factors, possibly genetic, may also play a role.
Clinical Presentation
Patients with POHS typically present with symptoms of blurred vision, scotoma (blind spot), and sometimes metamorphopsia (distorted vision). On ophthalmic examination, characteristic findings include small, round, punched-out chorioretinal scars known as "histo spots," peripapillary atrophy, and choroidal neovascularization.
Diagnosis
The diagnosis of POHS is primarily clinical, based on the characteristic ocular findings in the absence of systemic histoplasmosis or other causes of similar ocular findings. Fluorescein angiography and optical coherence tomography (OCT) may be used to confirm the diagnosis and assess the extent of choroidal neovascularization.
Treatment
The primary treatment for POHS is aimed at controlling the choroidal neovascularization, which can lead to severe vision loss if left untreated. This is typically achieved with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. Laser photocoagulation may also be used in some cases.
Prognosis
The prognosis for POHS varies depending on the extent of choroidal neovascularization and the response to treatment. With early detection and treatment, vision loss can often be prevented or minimized.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


